Founding Sponsors
Dexcom empowers people to take control of health through innovative biosensing technology. Founded in 1999, Dexcom has pioneered and set the standard in glucose biosensing for more than 25 years. Its technology has transformed how people manage diabetes and track their glucose, helping them feel more in control and live more confidently.
Dexcom. Discover what you’re made of. For more information, visit www.dexcom.com.
We’re a medicine company turning science into healing to make life better for people around the world.
Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing science to solve some of the world’s most significant health challenges. It all started nearly 150 years ago with a clear vision from founder Colonel Eli Lilly: “Take what you find here and make it better and better.”
But we’re not only dedicated to making medicines. We go beyond medicine to deliver innovative clinical trials that reflect the diversity of our world and work to ensure our medicines are accessible and affordable. Learn more at www.lilly.com/who-we-are/about-lilly.
Supporting Sponsors
Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to simplifying life for people with diabetes and other conditions through its Omnipod product platform. The Omnipod Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet’s latest innovation, the Omnipod® 5 Automated Insulin Delivery System, is a tubeless automated insulin delivery system, integrated with a continuous glucose monitor to manage blood sugar with no multiple daily injections, zero fingersticks, and is fully controlled by a compatible personal smartphone. Insulet also leverages the unique design of its Pod by tailoring its Omnipod technology platform for the delivery of non-insulin subcutaneous drugs across other therapeutic areas. For more information, please visit insulet.com and omnipod.com.
Provention Bio, Inc. (Nasdaq: PRVB) is a biopharmaceutical company focused on advancing the development of investigational therapies that may intercept and prevent debilitating and life-threatening immune-mediated disease. The Company’s pipeline includes a late-stage product candidate for type 1 diabetes (T1D) as well as clinical drug candidates in other autoimmune diseases, including celiac disease and lupus. We are proud to be part of the T1D ecosystem and are committed to bringing awareness to the importance and urgency of screening people with a family history of T1D for early-stage disease. Visit ProventionBio.com for more information or follow us on Twitter: @ProventionBio.
Tandem Diabetes Care creates new possibilities for people living with diabetes, their loved ones, and their healthcare providers through a positively different experience. We deliver innovative products and automated insulin delivery systems — including Tandem Mobi and the t:slim X2 — to people who require insulin therapy. For more information, visit tandemdiabetes.com.
Friend Level Sponsors
We are people with diabetes, parents of children with diabetes, caring allies from different backgrounds, professions, geographies, and political persuasions dedicated to improving the lives of all people impacted by diabetes. The Diabetes Leadership Council unites former leaders of national diabetes organizations, dedicated to securing effective, affordable health care and a discrimination-free environment for every person with diabetes.
MannKind is committed to providing products that allow people living with diabetes to experience life without limits. With Afrezza ® (insulin human) Inhalation Powder and V-Go ® wearable insulin delivery MannKind is focused on being a leader in mealtime control to address this serious unmet need within the diabetes community. Enrollment is currently underway for the INHALE-1 study that is evaluating Afrezza (in combination with basal insulin) for youth aged 4-17 living with type 1 or type 2 diabetes. With a passionate team of Mannitarians collaborating nationwide, we are on a mission to give people control of their health and the freedom to live life. Visit us at mannkindcorp.com and learn more about INHALE-1 at clinicaltrials.gov.
Peelz was developed in 2011 when Emily was diagnosed with type 1 diabetes. Together with her husband, Scott, they built a life and a company with a mission to make diabetes more personal, functional, and stylish.
Xeris Pharmaceuticals, Inc., the maker of Gvoke HypoPen® (glucagon injection), is dedicated to unlocking the potential of glucagon. We believe that our technology can have a profound impact on the lives of patients and their families. That’s why we are proud to be the first to develop liquid glucagon, but that’s just the beginning. We’re also studying how our formulation technology can impact patients with other conditions. We have a persistent drive to pursue solutions that have the potential to change lives. Get to know us and see how our technology is unlocking the potential of today’s medicines at www.xerispharma.com
